| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total operating expenses | 217,101 | 186,756 | 178,445 | 167,386 |
| Loss from operations | -46,109 | -36,714 | -56,982 | -62,624 |
| Interest expense, net | -1,120 | -1,834 | -2,431 | -1,978 |
| Loss on debt extinguishment | - | -10,385 | - | - |
| Loss before income taxes | -47,229 | -48,933 | -59,413 | -64,602 |
| Income tax benefit | - | -960 | - | - |
| Income tax benefit | - | -1,000 | - | - |
| Net loss | -47,229 | -47,973 | -59,413 | -64,602 |
| Net loss per common share, basic | -0.94 | -0.97 | -1.22 | -1.34 |
| Net loss per common share, diluted | -0.94 | -0.97 | -1.22 | -1.34 |
| Weighted average common shares outstanding, basic | 50,021,851 | 49,442,001 | 48,871,163 | 48,140,519 |
| Weighted average common shares outstanding, diluted | 50,021,851 | 49,442,001 | 48,871,163 | 48,140,519 |
Axsome Therapeutics, Inc. (AXSM)
Axsome Therapeutics, Inc. (AXSM)